New research from the Tufts Center for the Study of Drug Development provides insights into the unique challenges associated with executing oncology clinical trials: complex scientific and operating design characteristics, more internal reviews, significantly longer cycle times, poorer recruitment and retention rates, and higher numbers of protocol deviations and unplanned protocol amendments. Clinical teams need new strategies and solutions to address these unique challenges and optimize trial performance.
Register for this webinar to hear Ken Getz, director of Tufts CSDD and Richard Young, vice president of strategy, Vault CDMS at Veeva, as they discuss the results of this new research and its implications. See how your trial metrics compare to your oncology peers as Ken Getz shares new benchmark data, including endpoints and procedures, cycle times, screen failure and drop out rates, and the frequency of protocol amendments. Richard Young will outline what you should look for in an EDC so that you can:
• Build complex studies without risky custom functions
• Implement protocol amendments quickly and easily
• Accommodate platform, bucket, umbrella and adaptive trials
Come prepared with questions for our speakers to ask during the dedicated time for Q&A.
Presented by

Richard Young,
VP, Strategy, Vault CDMS, Veeva Systems
Richard Young is VP, Strategy, Vault CDMS at Veeva Systems. Young has over 25 years of expertise in data management and clinical strategy. His broad experience includes roles at Medidata where he focused on adaptive trials, risk-based monitoring, mobile health, and big data. He has also held operational roles at leading pharma and CRO organizations, including GlaxoWellcome, Novo Nordisk, and PAREXEL. Young holds a Bachelor of Science degree in biochemical sciences from Coventry University.

Kenneth A. Getz,
MBA, Deputy Director & Research Professor, Tufts Center for the Study of Drug Development (CSDD)
Mr. Getz is an internationally recognized expert on R&D and clinical trial management practices and trends, the global investigative site landscape, site management and patient recruitment and retention practices, and the worldwide market for outsourcing clinical research functions. Mr. Getz’s research studies on protocol design complexity and clinical research efficiency and effectiveness, conducted over the past two decades, are considered by many in the research-based life sciences industry to be pioneering work. His 20+ years of original research benchmarking R&D management practices, global outsourcing and the investigative site landscape have contributed to an industry-wide understanding of these critical markets and to improvements in management strategy and execution.